In a double-blind study versus placebo, the serotonergic agent m-chlorophen
ylpiperazine (mCPP) was administered to 20 healthy control subjects and 19
migraineurs to investigate the ability of mCPP (0.5 mg/kg) to induce typica
l migraine attacks. In the following 24 hours there were more migraines aft
er mCPP than after placebo in both groups. These findings are consistent wi
th involvement of 5HT(2B,2C,1A) receptor subtypes in the pathophysiology of
migraine.